Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature Chemical Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/nchembio.492PMID 21113170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drugs in Development for Hepatitis C

  2012cited by this paper
• Targeted covalent drugs of the kinase family.

  2010cited by this paper
• Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.

  2010cited by this paper
• Covalent modifiers: an orthogonal approach to drug design.

  2009cited by this paper
• MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

  2009cited by this paper
• Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins.

  2009cited by this paper
• Antiviral resistance and specifically targeted therapy for HCV (STAT‐C)

  2009cited by this paper
• Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

  2009cited by this paper
• In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

  2009cited by this paper
• Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.

  2008cited by this paper
• Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

  2008cited by this paper
• Differential Requirements of NS4A for Internal NS3 Cleavage and Polyprotein Processing of Hepatitis C Virus

  2007cited by this paper
• Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture.

  2007cited by this paper
• Hepatitis C viruses : genomes and molecular biology

  2006cited by this paper
• Targeting proteases: successes, failures and future prospects

  2006cited by this paper
• Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.

  2006cited by this paper
• Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:

  2006cited by this paper
• Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

  2006cited by this paper
• Mechanistic basis of enzyme-targeted drugs.

  2005cited by this paper
• An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

  2003cited by this paper
• Human and mouse proteases: a comparative genomic approach

  2003cited by this paper

• Classifying covalent protein binders by their targeted binding site.

  2024cites this paper
• Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

  2023cites this paper
• Non-Canonical Amino Acids in Analyses of Protease Structure and Function

  2023cites this paper
• Assessment of Covalently Binding Warhead Compounds in the Validation of the Cytomegalovirus Nuclear Egress Complex as an Antiviral Target

  2023cites this paper
• Controlled Protein Activities with Viral Proteases, Antiviral Peptides, and Antiviral Drugs.

  2023cites this paper
• A perspective on the changing landscape of HTS.

  2023cites this paper
• Controlled protein activities with viral proteases, antiviral peptides, and antiviral drugs

  2023cites this paper
• The Ascension of Targeted Covalent Inhibitors.

  2022cites this paper
• Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine.

  2022cites this paper
• Monomerization of Homodimeric Trefoil Factor 3 (TFF3) by an Aminonitrile Compound Inhibits TFF3-Dependent Cancer Cell Survival.

  2022cites this paper
• SMaSh: A Streptavidin Mass Shift Assay for Rapidly Quantifying Target Occupancy by Irreversible Inhibitors.

  2021cites this paper
• Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.

  2021cites this paper
• Identification of Potential Drug Targets of Broad-Spectrum Inhibitors with a Michael Acceptor Moiety Using Shotgun Proteomics

  2021cites this paper
• Delving into the Characteristic Features of “Menace” Mycobacterium tuberculosis Homologs: A Structural Dynamics and Proteomics Perspectives

  2020cites this paper
• Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective

  2020cites this paper
• Covalent peptides and proteins for therapeutics.

  2020cites this paper
• Covalent inhibitors: a rational approach to drug discovery

  2020cites this paper
• Investigation of some benzoquinazoline and quinazoline derivatives as novel inhibitors of HCV-NS3/4A protease: biological, molecular docking and QSAR studies

  2020cites this paper
• Discovery of dihydrofuranoallocolchicinoids - Highly potent antimitotic agents with low acute toxicity.

  2020cites this paper
• How the Local Environment of Functional Sites Regulates Protein Function.

  2020cites this paper
• Discovery of Targeted Covalent Natural Products against PLK1 by Herb-Based Screening

  2020cites this paper
• Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease

  2020cites this paper
• Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects.

  2019cites this paper
• Exploiting Cysteine Residues of SLC Membrane Transporters as Targets for Drugs

  2019cites this paper
• Hydroxylammonium derivatives for selective active-site lysine modification in the anti-virulence bacterial target DHQ1 enzyme

  2019cites this paper
• In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.

  2019cites this paper
• Can Cysteine Protease Cross-class Inhibitors Achieve Selectivity?

  2019cites this paper
• Sinteza i karakterizacija asimetričknih fumardiamida primakina i halogenanilina

  2019cites this paper
• Structural and functional determination of homologs of the Mycobacterium tuberculosis N-acetylglucosamine-6-phosphate deacetylase (NagA)

  2018cites this paper
• Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.

  2018cites this paper
• Current Strategies and Applications for Precision Drug Design

  2018cites this paper
• Targeting HCV polymerase: a structural and dynamic perspective into the mechanism of selective covalent inhibition

  2018cites this paper
• Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection

  2017cites this paper
• Discovery of host‐targeted covalent inhibitors of dengue virus

  2017cites this paper
• Novel peptidyl &agr;‐aminoalkylphosphonates as inhibitors of hepatitis C virus NS3/4A protease

  2017cites this paper
• Covalent inhibition of protein tyrosine phosphatases.

  2017cites this paper
• Covalent Allosteric Inactivation of Protein Tyrosine Phosphatase 1B (PTP1B) by an Inhibitor-Electrophile Conjugate.

  2017cites this paper
• Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.

  2017cites this paper
• Covalent inhibitors of LgtC: A blueprint for the discovery of non-substrate-like inhibitors for bacterial glycosyltransferases.

  2017cites this paper
• Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors

  2017cites this paper
• Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.

  2017cites this paper
• 2.11 – Allosteric Modulators

  2017cites this paper
• Computational study of non-catalytic T-loop pocket on CDK proteins for drug development

  2017cites this paper
• Design, Synthese und massenspektrometrische Analyse kovalenter und kovalent-reversibler Kinaseinhibitoren

  2017cites this paper
• In vitro effects of cysteine protease inhibitors on Trichomonas foetus-induced cytopathic changes in porcine intestinal epithelial cells.

  2016cites this paper
• Zielgerichtete kovalente Inhibitoren für das Wirkstoffdesign

  2016cites this paper
• Targeted Covalent Inhibitors for Drug Design.

  2016cites this paper
• Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals

  2016cites this paper
• Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery.

  2016cites this paper
• New drug design with covalent modifiers

  2016cites this paper
• Cytotoxic metabolites from the endophytic fungus Penicillium chermesinum: discovery of a cysteine-targeted Michael acceptor as a pharmacophore for fragment-based drug discovery, bioconjugation and click reactions

  2015cites this paper
• Selektive Hemmung des Immunproteasoms durch strukturbasierte Wahl eines nichtkatalytischen Cysteins als Angriffspunkt

  2015cites this paper
• First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

  2015cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1312 Discovery and evaluation of direct acting antivirals against hepatitis C virus

  2015cites this paper
• Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.

  2015cites this paper
• Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis.

  2015cites this paper
• Site-Specific Proteomic Mapping Identifies Selectively Modified Regulatory Cysteine Residues in Functionally Distinct Protein Networks.

  2015cites this paper
• Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine.

  2015cites this paper
• The design of covalent allosteric drugs.

  2015cites this paper
• Discovery and evaluation of direct acting antivirals against hepatitis C virus

  2015cites this paper
• Hepatitis C Virus: Structural Insights into Protease Inhibitor Efficacy and Drug Resistance: A Dissertation

  2015influential citation
• Drug discovery considerations in the development of covalent inhibitors.

  2014cites this paper
• A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.

  2014cites this paper
• Effective Virtual Screening Strategy toward Covalent Ligands: Identification of Novel NEDD8-Activating Enzyme Inhibitors

  2014cites this paper
• Palladium catalyzed direct allylation of azlactones with simple allylic alcohols in the absence of any activators

  2014cites this paper
• Design and Synthesis of N‐Acylated Aza‐Goniothalamin Derivatives and Evaluation of Their in vitro and in vivo Antitumor Activity

  2014cites this paper
• Discovery of Therapeutic Deubiquitylase Effector Molecules

  2014cites this paper
• Coupling protein engineering with probe design to inhibit and image matrix metalloproteinases with controlled specificity.

  2013cites this paper
• Limited and Degradative Proteolysis in the Context of Posttranslational Regulatory Networks: Current Technical and Conceptional Advances

  2013cites this paper
• COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT

  2013cites this paper
• Synthesis of piperlogs and analysis of their effects on cells.

  2013cites this paper
• Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.

  2013cites this paper
• Rational Design of Resorcylic Acid Lactone Analogues as Covalent MNK1/2 Kinase Inhibitors by Tuning the Reactivity of an Enamide Michael Acceptor

  2013cites this paper
• A coupled protein and probe engineering approach for selective inhibition and activity-based probe labeling of the caspases.

  2013cites this paper
• Identification of Novel Small Molecules as Inhibitors of Hepatitis C Virus by Structure-Based Virtual Screening

  2013cites this paper
• Electrophilic fragment-based design of reversible covalent kinase inhibitors.

  2013cites this paper
• Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity.

  2013cites this paper
• New Details of HCV NS3/4A Proteinase Functionality Revealed by a High-Throughput Cleavage Assay

  2012cites this paper
• Structural Framework for Covalent Inhibition of Clostridium botulinum Neurotoxin A by Targeting Cys165*

  2012cites this paper
• Viral proteases as targets for drug design.

  2012cites this paper
• Probing of Exosites Leads to Novel Inhibitor Scaffolds of HCV NS3/4A Proteinase

  2012influential citation
• Electrophilic natural products and their biological targets.

  2012cites this paper
• Targeted Covalent Enzyme Inhibitors

  2012cites this paper
• New approaches for dissecting protease functions to improve probe development and drug discovery

  2012cites this paper
• Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

  2012cites this paper
• The pharmacological landscape and therapeutic potential of serine hydrolases

  2012cites this paper
• Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors.

  2011cites this paper
• Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.

  2011cites this paper
• The resurgence of covalent drugs

  2011cites this paper
• Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.

  2011cites this paper
• A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.

  2011cites this paper
• Acta Universitatis Upsaliensis Uppsala 2015

  year unknowncites this paper